Nature Communications (Oct 2024)
The discovery and structural basis of two distinct state-dependent inhibitors of BamA
- Dawei Sun,
- Kelly M. Storek,
- Dimitry Tegunov,
- Ying Yang,
- Christopher P. Arthur,
- Matthew Johnson,
- John G. Quinn,
- Weijing Liu,
- Guanghui Han,
- Hany S. Girgis,
- Mary Kate Alexander,
- Austin K. Murchison,
- Stephanie Shriver,
- Christine Tam,
- Hiroshi Ijiri,
- Hiroko Inaba,
- Tatsuya Sano,
- Hayato Yanagida,
- Junichi Nishikawa,
- Christopher E. Heise,
- Wayne J. Fairbrother,
- Man-Wah Tan,
- Nicholas Skelton,
- Wendy Sandoval,
- Benjamin D. Sellers,
- Claudio Ciferri,
- Peter A. Smith,
- Patrick C. Reid,
- Christian N. Cunningham,
- Steven T. Rutherford,
- Jian Payandeh
Affiliations
- Dawei Sun
- Department of Structural Biology, Genentech Inc.
- Kelly M. Storek
- Department of Infectious Diseases, Genentech Inc.
- Dimitry Tegunov
- Department of Structural Biology, Genentech Inc.
- Ying Yang
- Department of Discovery Chemistry, Genentech Inc.
- Christopher P. Arthur
- Department of Structural Biology, Genentech Inc.
- Matthew Johnson
- Department of Structural Biology, Genentech Inc.
- John G. Quinn
- Department of Biochemical and Cellular Pharmacology, Genentech Inc.
- Weijing Liu
- Department of Microchemistry, Proteomics and Lipidomics, Genentech Inc.
- Guanghui Han
- Department of Microchemistry, Proteomics and Lipidomics, Genentech Inc.
- Hany S. Girgis
- Department of Infectious Diseases, Genentech Inc.
- Mary Kate Alexander
- Department of Infectious Diseases, Genentech Inc.
- Austin K. Murchison
- Department of Infectious Diseases, Genentech Inc.
- Stephanie Shriver
- Department of BioMolecular Resources, Genentech Inc.
- Christine Tam
- Department of BioMolecular Resources, Genentech Inc.
- Hiroshi Ijiri
- PeptiDream Inc.
- Hiroko Inaba
- PeptiDream Inc.
- Tatsuya Sano
- PeptiDream Inc.
- Hayato Yanagida
- PeptiDream Inc.
- Junichi Nishikawa
- PeptiDream Inc.
- Christopher E. Heise
- Department of Biochemical and Cellular Pharmacology, Genentech Inc.
- Wayne J. Fairbrother
- Department of Early Discovery Biochemistry, Genentech Inc.
- Man-Wah Tan
- Department of Infectious Diseases, Genentech Inc.
- Nicholas Skelton
- Department of Discovery Chemistry, Genentech Inc.
- Wendy Sandoval
- Department of Microchemistry, Proteomics and Lipidomics, Genentech Inc.
- Benjamin D. Sellers
- Department of Discovery Chemistry, Genentech Inc.
- Claudio Ciferri
- Department of Structural Biology, Genentech Inc.
- Peter A. Smith
- Department of Infectious Diseases, Genentech Inc.
- Patrick C. Reid
- PeptiDream Inc.
- Christian N. Cunningham
- Department of Peptide Therapeutics, Genentech Inc.
- Steven T. Rutherford
- Department of Infectious Diseases, Genentech Inc.
- Jian Payandeh
- Department of Structural Biology, Genentech Inc.
- DOI
- https://doi.org/10.1038/s41467-024-52512-1
- Journal volume & issue
-
Vol. 15,
no. 1
pp. 1 – 15
Abstract
Abstract BamA is the central component of the essential β-barrel assembly machine (BAM), a conserved multi-subunit complex that dynamically inserts and folds β-barrel proteins into the outer membrane of Gram-negative bacteria. Despite recent advances in our mechanistic and structural understanding of BamA, there are few potent and selective tool molecules that can bind to and modulate BamA activity. Here, we explored in vitro selection methods and different BamA/BAM protein formulations to discover peptide macrocycles that kill Escherichia coli by targeting extreme conformational states of BamA. Our studies show that Peptide Targeting BamA-1 (PTB1) targets an extracellular divalent cation-dependent binding site and locks BamA into a closed lateral gate conformation. By contrast, PTB2 targets a luminal binding site and traps BamA into an open lateral gate conformation. Our results will inform future antibiotic discovery efforts targeting BamA and provide a template to prospectively discover modulators of other dynamic integral membrane proteins.